Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole vs Risperidone in Adult Patients With Schizophrenia
NCT02758067Phase 3Withdrawn
- Sponsor
- Lundbeck
- Start
- Jun 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in schizophrenia (2 arms), sponsored by Lundbeck. Primary endpoint: Quality of Life Scale Total Score at 28 weeks. Planned start Jun 2016; status: withdrawn.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02758067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02758067.